

David L Straus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4112474/publications.pdf>

Version: 2024-02-01

152
papers

4,255
citations

126907

33
h-index

128289

60
g-index

154
all docs

154
docs citations

154
times ranked

3656
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	7.0	13
2	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
3	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	1.6	9
4	Assessing the toxicity of peracetic acid to early Atlantic salmon (<i>Salmo salar</i>) life stages. <i>Aquaculture Research</i> , 2022, 53, 5097-5104.	1.8	1
5	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
6	Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7528-7528.	1.6	0
7	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
8	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	4.6	83
9	IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 873-878.	0.4	1
10	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	4.1	16
11	Effect of water hardness/alkalinity and humic substances on the toxicity of peracetic acid to zebrafish embryos and pathogenic isolates. <i>Aquaculture Reports</i> , 2021, 21, 100900.	1.7	4
12	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0
13	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2447-2447.	1.4	1
14	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.	1.4	0
15	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021, 138, 4578-4578.	1.4	0
16	Development and comparison of loop-mediated isothermal amplification with quantitative PCR for the specific detection of <i>Saprolegnia</i> spp.. <i>PLoS ONE</i> , 2021, 16, e0250808.	2.5	3
17	Inhibiting fungus on largemouth bass eggs with copper sulfate and its toxicity to fry and juveniles. <i>Journal of the World Aquaculture Society</i> , 2020, 51, 214-223.	2.4	5
18	Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody. <i>Leukemia and Lymphoma</i> , 2020, 61, 364-369.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Sustainable aquaculture requires environmentalâ€friendly treatment strategies for fish diseases. <i>Reviews in Aquaculture</i> , 2020, 12, 943-965.	9.0	159
20	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
21	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
22	Treatment of Newly Diagnosed Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S87-S88.	0.4	1
23	Next Questions â€ Classical Hodgkin Lymphoma (cHL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S103-S104.	0.4	0
24	Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. <i>Leukemia and Lymphoma</i> , 2020, 61, 3331-3341.	1.3	17
25	ABVD vs BEACOPP escalated in advancedâ€stage Hodgkinâ€™s lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	4.1	6
26	Antioxidative, histological and immunological responses of rainbow trout after periodic and continuous exposures to a peracetic acid-based disinfectant. <i>Aquaculture</i> , 2020, 520, 734956.	3.5	16
27	Positron-emission tomographyâ€based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	2.8	21
28	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	1.4	86
29	IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. <i>Blood</i> , 2020, 136, 10-10.	1.4	1
30	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020, 136, 26-28.	1.4	5
31	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	1.4	5
32	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
33	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
34	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	1.4	1
35	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
36	Highlights in Hodgkin lymphoma from the 61st American Society of Hematology Annual Meeting: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 6, 20-23.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Complications Associated with Mediastinal Radiation. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 31.	0.9	29
38	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood, 2019, 133, 2121-2129.	1.4	46
39	Evaluating the effects of prolonged peracetic acid dosing on water quality and rainbow trout <i>Oncorhynchus mykiss</i> performance in recirculation aquaculture systems. Aquacultural Engineering, 2019, 84, 117-127.	3.1	17
40	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	7.0	26
41	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood, 2019, 134, 2834-2834.	1.4	1
42	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). Blood, 2019, 134, 2826-2826.	1.4	2
43	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. Blood, 2019, 134, 4019-4019.	1.4	20
44	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. Blood, 2019, 134, 2837-2837.	1.4	6
45	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. Blood, 2019, 134, 1555-1555.	1.4	4
46	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. Blood, 2019, 134, 22-22.	1.4	7
47	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. Blood, 2019, 134, 1619-1619.	1.4	9
48	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. Blood, 2019, 134, 2850-2850.	1.4	1
49	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	1.4	0
50	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 2904-2904.	1.4	2
51	Confirmation that pulse and continuous peracetic acid administration does not disrupt the acute stress response in rainbow trout. Aquaculture, 2018, 492, 190-194.	3.5	20
52	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood, 2018, 131, 1805-1808.	1.4	49
53	Toxicity of Peracetic Acid to Fish: Variation among Species and Impact of Water Chemistry. Journal of the World Aquaculture Society, 2018, 49, 715-724.	2.4	30
54	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 2018, 8, 60.	6.2	25

#	ARTICLE	IF	CITATIONS
55	Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. <i>Blood</i> , 2018, 132, 1647-1647.	1.4	10
56	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6
57	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 2904-2904.	1.4	4
58	Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 2880-2880.	1.4	1
59	Dietary copper effects survival of channel catfish challenged with <i>Flavobacterium columnare</i> . <i>Aquaculture Research</i> , 2017, 48, 1751-1758.	1.8	10
60	Pulse versus continuous peracetic acid applications: Effects on rainbow trout performance, biofilm formation and water quality. <i>Aquacultural Engineering</i> , 2017, 77, 72-79.	3.1	33
61	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
62	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	1.4	3
63	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	1.6	239
64	Peracetic acid is a suitable disinfectant for recirculating fish-microalgae integrated multi-trophic aquaculture systems. <i>Aquaculture Reports</i> , 2016, 4, 136-142.	1.7	24
65	Use of Copper Sulfate to Control Egg Saprolegniasis at a Commercial Sunshine Bass Hatchery. <i>North American Journal of Aquaculture</i> , 2016, 78, 243-250.	1.4	14
66	Prospective Study of ¹⁸ F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	5.0	41
67	Radiation Therapy for Hodgkin Lymphoma—Can It Be Administered More Safely if Necessary?. <i>JAMA Oncology</i> , 2016, 2, 169.	7.1	5
68	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	1.4	2
69	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). <i>Blood</i> , 2016, 128, 1778-1778.	1.4	3
70	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4
71	Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1774-1774.	1.4	0
72	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016, 128, 4119-4119.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Comparison of the Toxicity of Wofasteril Peracetic Acid Formulations E400, E250, and Lspez to <i>Daphnia magna</i> , with Emphasis on the Effect of Hydrogen Peroxide. North American Journal of Aquaculture, 2015, 77, 128-135.	1.4	19
74	The Effectiveness of Flow-Through or Static Copper Sulfate Treatments on the Survival of Golden Shiners and Fathead Minnows Infected with <i>Flavobacterium columnare</i> . North American Journal of Aquaculture, 2015, 77, 90-95.	1.4	2
75	Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood. Journal of the National Cancer Institute, 2015, 107, djv018-djv018.	6.3	38
76	Water hardness influences <i>Flavobacterium columnare</i> pathogenesis in channel catfish. Aquaculture, 2015, 435, 252-256.	3.5	14
77	Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). Blood, 2015, 126, 578-578.	1.4	21
78	Growth inhibition of <i>Aeromonas salmonicida</i> and <i>Yersinia ruckeri</i> by disinfectants containing peracetic acid. Diseases of Aquatic Organisms, 2015, 113, 207-213.	1.0	22
79	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. Blood, 2015, 126, 2668-2668.	1.4	0
80	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. Blood, 2015, 126, 2691-2691.	1.4	0
81	Comparative Effects of Copper Sulfate or Potassium Permanganate on Channel Catfish Concurrently Infected with <i>Flavobacterium columnare</i> and <i>Ichthyobodo necator</i> . Journal of Applied Aquaculture, 2014, 26, 71-83.	1.4	7
82	Salinity, dissolved organic carbon and water hardness affect peracetic acid (PAA) degradation in aqueous solutions. Aquacultural Engineering, 2014, 60, 35-40.	3.1	27
83	Effectiveness of copper sulphate, potassium permanganate and peracetic acid to reduce mortality and infestation of <i>Ichthyobodo necator</i> in channel catfish <i>Ictalurus punctatus</i> (Rafinesque). Tj ETQq1 1 0.784314 rgBT14/Overlo	1.4	0
84	Effect of water hardness on peracetic acid toxicity to zebrafish, <i>Danio rerio</i> , embryos. Aquaculture International, 2013, 21, 679-686.	2.2	16
85	Safety of Feed Treated with 17 β -Methyltestosterone (17MT) to Larval Nile Tilapia. North American Journal of Aquaculture, 2013, 75, 212-219.	1.4	8
86	Peracetic acid degradation in freshwater aquaculture systems and possible practical implications. Aquacultural Engineering, 2013, 53, 65-71.	3.1	57
87	Basal polarization of the mucosal compartment in <i>Flavobacterium columnare</i> susceptible and resistant channel catfish (<i>Ictalurus punctatus</i>). Molecular Immunology, 2013, 56, 317-327.	2.2	100
88	Pretreating Channel Catfish with Copper Sulfate Affects Susceptibility to Columnaris Disease. North American Journal of Aquaculture, 2013, 75, 205-211.	1.4	11
89	Putative roles for a rhamnose binding lectin in <i>Flavobacterium columnare</i> pathogenesis in channel catfish <i>Ictalurus punctatus</i> . Fish and Shellfish Immunology, 2012, 33, 1008-1015.	3.6	76
90	Effectiveness of Copper Sulfate and Potassium Permanganate on Channel Catfish Infected with <i>Flavobacterium columnare</i> . North American Journal of Aquaculture, 2012, 74, 320-329.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Safety of Copper Sulfate to Channel Catfish Eggs. North American Journal of Aquaculture, 2012, 74, 60-64.	1.4	6
92	Safety of Aquaflorâ€Medicated Feed to Sunshine Bass. North American Journal of Aquaculture, 2012, 74, 1-7.	1.4	20
93	Acute toxicity and histopathology of channel catfish fry exposed to peracetic acid. Aquaculture, 2012, 342-343, 134-138.	3.5	25
94	Hatch rate of channel catfish <i>Ictalurus punctatus</i> (Rafinesque 1818) eggs treated with 100â€mgâ€fLâˆ¹ copper sulphate pentahydrate. Aquaculture Research, 2012, 43, 14-18.	1.8	15
95	Peracetic acid is effective for controlling fungus on channel catfish eggs. Journal of Fish Diseases, 2012, 35, 505-511.	1.9	27
96	Evaluation of a 4-h static copper sulphate treatment against experimental infection of <i>Flavobacterium columnare</i> in channel catfish (<i>Ictalurus punctatus</i>). Aquaculture Research, 2012, 43, 688-695.	1.8	6
97	Reduction of <i>in vitro</i> growth in <i>Flavobacterium columnare</i> and <i>Saprolegnia parasitica</i> by products containing peracetic acid. Aquaculture Research, 2012, 43, 1861-1866.	1.8	34
98	CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.. Blood, 2012, 120, 2706-2706.	1.4	3
99	Dose-Confirmation of Copper Sulfate for Treating Fungus on Channel Catfish, <i>Ictalurus punctatus</i> , Eggs at a Commercial Hatchery. Journal of Applied Aquaculture, 2011, 23, 199-206.	1.4	7
100	The Effect of High Total Ammonia Concentration on the Survival of Channel Catfish Experimentally Infected with <i>Flavobacterium columnare</i> . Journal of Aquatic Animal Health, 2011, 23, 162-168.	1.4	34
101	Toxicity of Rotenone to Giant River Freshwater Prawn <i>Macrobrachium rosenbergii</i> . North American Journal of Aquaculture, 2011, 73, 159-163.	1.4	3
102	Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience. Blood, 2011, 118, 2688-2688.	1.4	6
103	Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?.. Blood, 2011, 118, 3644-3644.	1.4	3
104	Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL). Blood, 2011, 118, 882-882.	1.4	0
105	Comparison of Percent Hatch and Fungal Infestation in Channel Catfish Eggs after Copper Sulfate, Diquat Bromide, Formalin, and Hydrogen Peroxide Treatment. North American Journal of Aquaculture, 2010, 72, 201-206.	1.4	6
106	Evaluation of continuous 4-day exposure to peracetic acid as a treatment for <i>Ichthyophthirius multifiliis</i> . Parasitology Research, 2010, 106, 539-542.	1.6	41
107	Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response. Blood, 2010, 116, 4158-4158.	1.4	9
108	The Effect of Hydrogen Peroxide on the Hatch Rate and <i>Saprolegnia</i> spp. Infestation of Channel Catfish Eggs. North American Journal of Aquaculture, 2009, 71, 276-280.	1.4	17

#	ARTICLE	IF	CITATIONS
109	Copper sulfate toxicity to two isolates of <i>Ichthyophthirius multifiliis</i> relative to alkalinity. <i>Diseases of Aquatic Organisms</i> , 2009, 83, 31-36.	1.0	17
110	Optimizing Copper Sulfate Treatments for Fungus Control on Channel Catfish Eggs. <i>Journal of Aquatic Animal Health</i> , 2009, 21, 91-97.	1.4	25
111	Acute toxicity of peracetic acid (PAA) formulations to <i>Ichthyophthirius multifiliis</i> theronts. <i>Parasitology Research</i> , 2009, 104, 1237-1241.	1.6	53
112	Evaluation of the therapeutic effect of potassium permanganate at early stages of an experimental acute infection of <i>Flavobacterium columnare</i> in channel catfish, <i>Ictalurus punctatus</i> (Rafinesque). <i>Aquaculture Research</i> , 2009, 41, 1479.	1.8	2
113	Laboratory Dose Confirmation of Copper Sulfate for Treating Fungus on Channel Catfish Eggs. <i>North American Journal of Aquaculture</i> , 2009, 71, 333-338.	1.4	17
114	Comparison of Copper Sulfate Concentrations to Control Ichthyophthiriasis in Fingerling Channel Catfish. <i>Journal of Applied Aquaculture</i> , 2008, 20, 272-284.	1.4	14
115	Copper Sulfate Toxicity to Channel Catfish Fry: Yolk Sac versus Swim-Up Fry. <i>North American Journal of Aquaculture</i> , 2008, 70, 323-327.	1.4	15
116	Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. <i>Cancer</i> , 2007, 109, 1799-1803.	4.1	82
117	Species Sensitivity to Copper. <i>Journal of Applied Aquaculture</i> , 2006, 18, 89-99.	1.4	14
118	Fingerling Channel Catfish. <i>Toxicology Mechanisms and Methods</i> , 2006, 16, 235-239.	2.7	3
119	Solid and Liquid Formulations of Copper Sulfate: Efficacy at High and Low Alkalinities. <i>North American Journal of Aquaculture</i> , 2006, 68, 359-363.	1.4	7
120	Treatment of early-stage nonbulky Hodgkin lymphoma. <i>Current Opinion in Oncology</i> , 2006, 18, 432-436.	2.4	6
121	Management of Early Stage Hodgkin's Lymphoma. , 2006, 131, 317-332.		0
122	Treatment of Anemia with Erythropoietic Agents in Patients with Hematologic Malignancies. <i>Supportive Cancer Therapy</i> , 2005, 2, 215-224.	0.3	1
123	Comparison of the Acute Toxicity of Potassium Permanganate to Hybrid Striped Bass in Well Water and Diluted Well Water. <i>Journal of the World Aquaculture Society</i> , 2004, 35, 55-60.	2.4	17
124	Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999. <i>Blood</i> , 2004, 104, 614-614.	1.4	4
125	Epoetin Alfa Therapy for Patients with Hematologic Malignancies and Mild Anemia. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, S13-S17.	2.1	4
126	Gallium nitrate in the treatment of lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 25-33.	2.2	102

#	ARTICLE	IF	CITATIONS
127	Efficacy of Potassium Permanganate in Treating Ichthyophthiriasis in Channel Catfish. <i>Journal of Aquatic Animal Health</i> , 2002, 14, 145-148.	1.4	33
128	Histological and Hematological Evaluation of Potassium Permanganate Exposure in Channel Catfish. <i>Journal of Aquatic Animal Health</i> , 2002, 14, 134-144.	1.4	29
129	Biomarkers as Predictors in Health and Ecological Risk Assessment. <i>Human and Ecological Risk Assessment (HERA)</i> , 2002, 8, 165-176.	3.4	54
130	Epoetin alfa as a supportive measure in hematologic malignancies. <i>Seminars in Hematology</i> , 2002, 39, 25-31.	3.4	9
131	Effect of Exposure to Potassium Permanganate on Stress Indicators in Channel Catfish <i>Ictalurus punctatus</i> . <i>Journal of the World Aquaculture Society</i> , 2002, 33, 1-9.	2.4	23
132	Prevention of an Initial Infestation of <i>Ichthyophthirius multifiliis</i> in Channel Catfish and Blue Tilapia by Potassium Permanganate Treatment. <i>North American Journal of Aquaculture</i> , 2001, 63, 11-16.	1.4	42
133	Hepatic microsomal desulfuration and dearylation of chlorpyrifos and parathion in fingerling channel catfish: lack of effect from Aroclor 1254. <i>Aquatic Toxicology</i> , 2000, 50, 141-151.	4.0	19
134	Inhibition and aging of channel catfish brain acetylcholinesterase following exposure to two phosphorothionate insecticides and their active metabolites. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1995, 45, 325-336.	2.3	19
135	Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy. <i>Cancer</i> , 1993, 71, 2332-2334.	4.1	21
136	Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. <i>Cancer</i> , 1993, 71, 2342-2350.	4.1	86
137	Acute Toxicity of Copper Sulfate and Chelated Copper to Channel Catfish <i>Ictalurus punctatus</i> . <i>Journal of the World Aquaculture Society</i> , 1993, 24, 390-395.	2.4	67
138	On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data. <i>Journal of the American Statistical Association</i> , 1993, 88, 400-409.	3.1	420
139	Prevention of <i>Ichthyophthirius multifiliis</i> Infestation in Channel Catfish Fingerlings by Copper Sulfate Treatment. <i>Journal of Aquatic Animal Health</i> , 1993, 5, 152-154.	1.4	39
140	On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples From Clinical Oncology Data. <i>Journal of the American Statistical Association</i> , 1993, 88, 400.	3.1	79
141	Primary lymphoma of the liver. <i>Cancer</i> , 1988, 61, 370-375.	4.1	115
142	AIDS-related lymphoid neoplasia. The memorial hospital experience. <i>Cancer</i> , 1988, 61, 2325-2337.	4.1	261
143	Primary lymphoma of the spleen: Clinical features and outcome after splenectomy. <i>Cancer</i> , 1988, 62, 1433-1438.	4.1	101
144	Localized non-Hodgkin's lymphoma of the breast. <i>Cancer</i> , 1987, 59, 351-354.	4.1	54

#	ARTICLE	IF	CITATIONS
145	Value of splenectomy in non-Hodgkin's lymphoma. <i>Cancer</i> , 1985, 55, 1256-1264.	4.1	13
146	Treatment of diffuse poorly differentiated lymphocytic lymphoma an analysis of prognostic variables. <i>Cancer</i> , 1984, 53, 2404-2412.	4.1	23
147	NHL-3 protocol six-drug combination chemotherapy for non-hodgkin's lymphoma. <i>Cancer</i> , 1984, 53, 2592-2600.	4.1	18
148	The non-Hodgkin's lymphomas I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969. <i>Cancer</i> , 1983, 51, 101-109.	4.1	101
149	Osteonecrosis in patients with malignant lymphoma: A review of twenty-five cases. <i>Cancer</i> , 1981, 48, 1245-1250.	4.1	55
150	Angioimmunoblastic lymphadenopathy: Clinical spectrum of disease. <i>Cancer</i> , 1981, 48, 2493-2498.	4.1	49
151	The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease. A follow-up report. <i>Cancer</i> , 1980, 46, 233-240.	4.1	38
152	Evidence-Based Treatment of Burkitt Lymphoma in Adults. , 0, , 311-316.		0